GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 189 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $8,882,000 | -53.0% | 130,434 | -77.9% | 0.01% | -16.7% |
| Q2 2022 | $18,898,000 | +793.9% | 591,476 | +869.0% | 0.01% | +500.0% |
| Q1 2022 | $2,114,000 | -52.0% | 61,038 | -59.4% | 0.00% | +100.0% |
| Q4 2021 | $4,402,000 | +113.9% | 150,376 | +86.3% | 0.00% | 0.0% |
| Q3 2021 | $2,058,000 | -39.3% | 80,704 | -16.6% | 0.00% | -50.0% |
| Q2 2021 | $3,388,000 | +9.3% | 96,771 | +27.2% | 0.00% | 0.0% |
| Q1 2021 | $3,100,000 | -52.5% | 76,049 | -49.5% | 0.00% | -50.0% |
| Q4 2020 | $6,528,000 | +63.1% | 150,741 | +107.6% | 0.00% | +100.0% |
| Q3 2020 | $4,002,000 | +492.9% | 72,597 | +578.5% | 0.00% | +100.0% |
| Q2 2020 | $675,000 | -86.3% | 10,699 | -88.9% | 0.00% | -75.0% |
| Q1 2020 | $4,938,000 | -68.1% | 96,607 | -50.4% | 0.00% | -50.0% |
| Q4 2019 | $15,492,000 | +796.0% | 194,899 | +447.2% | 0.01% | +700.0% |
| Q3 2019 | $1,729,000 | -66.2% | 35,620 | -63.3% | 0.00% | -66.7% |
| Q2 2019 | $5,112,000 | +380.9% | 97,178 | +384.4% | 0.00% | +200.0% |
| Q1 2019 | $1,063,000 | -66.8% | 20,063 | -74.3% | 0.00% | -66.7% |
| Q4 2018 | $3,199,000 | -33.7% | 77,937 | -38.6% | 0.00% | 0.0% |
| Q3 2018 | $4,828,000 | -24.4% | 127,030 | -10.1% | 0.00% | -50.0% |
| Q2 2018 | $6,387,000 | +315.0% | 141,294 | +343.4% | 0.01% | +500.0% |
| Q1 2018 | $1,539,000 | -67.2% | 31,867 | -73.3% | 0.00% | -75.0% |
| Q4 2017 | $4,698,000 | +63.5% | 119,393 | +29.1% | 0.00% | +33.3% |
| Q3 2017 | $2,873,000 | +3.5% | 92,504 | -8.8% | 0.00% | 0.0% |
| Q2 2017 | $2,776,000 | -46.8% | 101,476 | -28.4% | 0.00% | -50.0% |
| Q1 2017 | $5,221,000 | +1179.7% | 141,680 | +400.2% | 0.01% | – |
| Q4 2016 | $408,000 | +537.5% | 28,323 | +914.8% | 0.00% | – |
| Q3 2016 | $64,000 | +60.0% | 2,791 | +15.8% | 0.00% | – |
| Q2 2016 | $40,000 | -41.2% | 2,410 | +48.8% | 0.00% | – |
| Q3 2015 | $68,000 | – | 1,620 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
| Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
| Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
| Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
| HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
| Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
| ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
| HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
| Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
| Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |